Novartis Pharmaceuticals rose nearly 2% in the premarket to $132.73. According to the news, Novartis Pharmaceuticals and British biotech company Relation Therapeutics have reached a deal of more than 1.7 billion US dollars to help find drug targets to treat allergic diseases. The deal aims to combine Novartis Pharmaceuticals' expertise in immunodermatology with Relation's drug discovery artificial intelligence platform, which uses patient data, including human tissue, to reveal the genetic basis of disease presentation.

Novartis Pharmaceuticals rose nearly 2% in the premarket to $132.73. According to the news, Novartis Pharmaceuticals and British biotech company Relation Therapeutics have reached a deal of more than 1.7 billion US dollars to help find drug targets to treat allergic diseases. The deal aims to combine Novartis Pharmaceuticals' expertise in immunodermatology with Relation's drug discovery artificial intelligence platform, which uses patient data, including human tissue, to reveal the genetic basis of disease presentation.